Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

W Greenhalf, P Ghaneh… - Journal of the …, 2014 - academic.oup.com
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …
被引用次数：297 相关文章

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

W Greenhalf, P Ghaneh, JP Neoptolemos… - Journal of the National …, 2014 - diva-portal.org
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

W Greenhalf, P Ghaneh, JP Neoptolemos… - JOURNAL OF THE …, 2014 - iris.univr.it
BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

W Greenhalf, P Ghaneh, JP Neoptolemos, DH Palmer… - 2013 - ahro.austin.org.au
Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma
may predict survival in patients who receive adjuvant gemcitabine after resection …
[PDF] oup.com

[PDF][PDF] Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

W Greenhalf, P Ghaneh… - Journal Of The …, 2014 - academic.oup.com
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …

[引用][C] Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the ESPAC-3 trial.

W Greenhalf, P Ghaneh, J Neoptolemos, D Palmer… - 2013 - christie.openrepository.com
Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the
ESPAC-3 trial. Toggle navigation Login Toggle navigation View Item Home The Christie …

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

W Greenhalf, P Ghaneh… - Journal of the …, 2014 - research.manchester.ac.uk
BackgroundHuman equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

W Greenhalf, P Ghaneh, JP Neoptolemos… - JNCI-Journal of the …, 2014 - eprints.ncl.ac.uk
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

W Greenhalf, P Ghaneh, J Neoptolemos… - Journal of the National …, 2014 - ora.ox.ac.uk
BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

W Greenhalf, P Ghaneh, JP Neoptolemos, DH Palmer… - 2014 - pubmed.ncbi.nlm.nih.gov
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …